SCHEMBL6110656

SCHEMBL6110656

CCOC(=O)c1c(O)c2cc(Br)ccc2c(=O)n1CC(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.50
ALDH1A1 P00352 3/20 0.50
MAPT P10636 1/20 0.46
ATM Q13315 1/20 0.46
DPP4 P27487 1/20 0.45
LMNA P02545 1/20 0.42
GABRA1 P14867 1/20 0.41
GABRB1 P18505 1/20 0.41
GABRA3 P34903 1/20 0.41
GABRB2 P47870 1/20 0.41
MAPK8 P45983 6/20 0.41
ELANE P08246 2/20 0.40
KDM4E B2RXH2 1/20 0.40
KMT2A Q03164 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
TSHR P16473 1/20 0.39
HSD17B10 Q99714 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
APAF1 O14727 1/20 0.38
SMAD3 P84022 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5236008 0.86 LMNA (0.39) SMN1; SMN2ALDH1A1MAPTDPP4LMNA
SCHEMBL5238679 0.84 ALDH1A1 (0.50) SMN1; SMN2ALDH1A1MAPTATMLMNA
SCHEMBL5239480 0.84 SMN1; SMN2 (0.44) SMN1; SMN2ALDH1A1MAPTATMDPP4
SCHEMBL5236533 0.82 ALDH1A1 (0.41) SMN1; SMN2ALDH1A1MAPTKDM4EKMT2A
SCHEMBL5238321 0.82 MAPK8 (0.53) SMN1; SMN2ALDH1A1MAPTATMLMNA
SCHEMBL5237248 0.82 LMNA (0.39) SMN1; SMN2ALDH1A1MAPTDPP4LMNA
SCHEMBL5576875 0.80 ALDH1A1 (0.50) SMN1; SMN2ALDH1A1MAPTATMLMNA
SCHEMBL5238135 0.79 NMT1 (0.47) ALDH1A1DPP4LMNAGABRA1GABRA3
SCHEMBL24054558 0.79 ALDH1A1 (0.76) SMN1; SMN2ALDH1A1MAPTATMLMNA
SCHEMBL30198363 0.79 ALDH1A1 (0.76) SMN1; SMN2ALDH1A1MAPTATMLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7034039-B2 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-04-25 US disclosed
CN-1500080-A Fused heterocyclic compounds ����ҩƷ��ҵ��ʽ���� 2004-05-26 CN disclosed
US-20040082607-A1 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082607-A1 Fused heterocyclic compounds DPP7, DPP4, METAP1 SMN1; SMN2 4002/4885ALDH1A1 387/4885MAPT 4855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.